BMY-28100对儿科感染常见分离株的体外活性。
In vitro activity of BMY-28100 against common isolates from pediatric infections.
作者信息
Scribner R K, Marks M I, Finkhouse B D
出版信息
Antimicrob Agents Chemother. 1987 Apr;31(4):630-1. doi: 10.1128/AAC.31.4.630.
Abstract
The antibacterial activity of BMY-28100, a new oral cephalosporin, was measured against 300 bacterial isolates from pediatric infections by standard agar dilution methodology. The effect of inoculum size on activity was also assessed. BMY-28100 was more active than cephalexin or cefaclor against all bacterial species tested.
摘要
采用标准琼脂稀释法测定了新型口服头孢菌素BMY-28100对300株儿科感染分离菌的抗菌活性。还评估了接种量对活性的影响。BMY-28100对所有测试的细菌种类的活性均高于头孢氨苄或头孢克洛。
相似文献
1
In vitro activity of BMY-28100 against common isolates from pediatric infections.BMY-28100对儿科感染常见分离株的体外活性。
Antimicrob Agents Chemother. 1987 Apr;31(4):630-1. doi: 10.1128/AAC.31.4.630.
2
In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY-28100的体外和体内评价
J Antibiot (Tokyo). 1987 Aug;40(8):1175-83. doi: 10.7164/antibiotics.40.1175.
3
BMY 28100, a new oral cephalosporin.BMY 28100，一种新型口服头孢菌素。
Antimicrob Agents Chemother. 1987 Feb;31(2):238-43. doi: 10.1128/AAC.31.2.238.
4
BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.新型口服头孢菌素BMY-28100：对近7000株近期临床分离菌株的抗菌活性、与其他口服制剂的相对效价以及对产β-内酰胺酶分离菌株的活性
Diagn Microbiol Infect Dis. 1988 Jan;9(1):11-26. doi: 10.1016/0732-8893(88)90056-9.
5
In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.BMY-28142对儿科病原体的体外活性，包括来自囊性纤维化痰液的分离株。
Antimicrob Agents Chemother. 1985 Jul;28(1):58-63. doi: 10.1128/AAC.28.1.58.
6
In vitro activity of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY - 28100的体外活性
Antimicrob Agents Chemother. 1987 Apr;31(4):653-6. doi: 10.1128/AAC.31.4.653.
7
Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.新型口服头孢菌素BMY-28100的抗菌活性比较
Antimicrob Agents Chemother. 1987 Mar;31(3):480-3. doi: 10.1128/AAC.31.3.480.
8
Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.新型头孢菌素BMY 28142与其他广谱β-内酰胺类抗生素的比较。
Antimicrob Agents Chemother. 1985 Feb;27(2):207-16. doi: 10.1128/AAC.27.2.207.
9
In vitro activity of Ro 15-8074 and Ro 19-5247 in comparison to cefaclor and cefalexin.
Infection. 1987 Mar-Apr;15(2):122-4. doi: 10.1007/BF01650213.
10
In vitro activity of BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY-28100的体外活性
Chemotherapy. 1988;34(1):27-9. doi: 10.1159/000238543.
引用本文的文献
1
Five-day versus ten-day treatment of acute otitis media with cefprozil.头孢丙烯治疗急性中耳炎的五日疗法与十日疗法对比
Eur J Clin Microbiol Infect Dis. 1997 Apr;16(4):283-6. doi: 10.1007/BF01695632.
2
Penetration of cefprozil into tonsillar and adenoidal tissues.头孢丙烯在扁桃体和腺样体组织中的渗透情况。
Antimicrob Agents Chemother. 1993 May;37(5):1180-3. doi: 10.1128/AAC.37.5.1180.
3
Comparative studies of cefprozil in the management of skin and soft-tissue infections.头孢丙烯治疗皮肤和软组织感染的对比研究。
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):866-71. doi: 10.1007/BF02111354.
4
Multi-investigator evaluation of the efficacy and safety of cefprozil, amoxicillin-clavulanate, cefixime and cefaclor in the treatment of acute otitis media.多位研究者对头孢丙烯、阿莫西林-克拉维酸、头孢克肟和头孢克洛治疗急性中耳炎的疗效和安全性进行的评估。
Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):857-65. doi: 10.1007/BF02111353.
5
Penetration of cefprozil into middle ear fluid of patients with otitis media.头孢丙烯在中耳炎患者中耳液中的渗透情况。
Antimicrob Agents Chemother. 1994 Sep;38(9):2210-2. doi: 10.1128/AAC.38.9.2210.
6
Cefprozil. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic potential.头孢丙烯。对其抗菌活性、药代动力学特性及治疗潜力的综述。
Drugs. 1993 Feb;45(2):295-317. doi: 10.2165/00003495-199345020-00008.
7
Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin.新型口服头孢菌素BMY-28100的纸片扩散药敏试验及肉汤微量稀释法质量控制指南
J Clin Microbiol. 1987 Nov;25(11):2211-3. doi: 10.1128/jcm.25.11.2211-2213.1987.
8
Phase I study of multiple-dose cefprozil and comparison with cefaclor.多剂量头孢丙烯的I期研究及其与头孢克洛的比较。
Antimicrob Agents Chemother. 1990 Jun;34(6):1198-203. doi: 10.1128/AAC.34.6.1198.
9
Phase I study of single-dose BMY-28100, a new oral cephalosporin.新型口服头孢菌素BMY-28100单剂量的I期研究。
Antimicrob Agents Chemother. 1990 Feb;34(2):202-5. doi: 10.1128/AAC.34.2.202.
10
Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women.头孢丙烯与头孢克洛治疗女性急性尿路感染的比较。
Antimicrob Agents Chemother. 1991 Sep;35(9):1940-2. doi: 10.1128/AAC.35.9.1940.
本文引用的文献
1
Inoculum size effect on the MIC of cefoperazone, moxalactam, cefotaxime, cefoxitin and cephalothin for 118 strains of Haemophilus influenzae including 'tolerant' micro-organisms.接种量对118株流感嗜血杆菌（包括“耐受”微生物）的头孢哌酮、拉氧头孢、头孢噻肟、头孢西丁和头孢噻吩最低抑菌浓度的影响
J Antimicrob Chemother. 1982 Nov;10(5):397-402. doi: 10.1093/jac/10.5.397.
2
In vitro activity of BMY-28142 against pediatric pathogens, including isolates from cystic fibrosis sputum.BMY-28142对儿科病原体的体外活性，包括来自囊性纤维化痰液的分离株。
Antimicrob Agents Chemother. 1985 Jul;28(1):58-63. doi: 10.1128/AAC.28.1.58.
Zotero 插件